THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult your licensed securities dealer, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your securities in Wai Yuen Tong Medicine Holdings Limited (位元堂藥業控股有限公司*), you should at once hand this circular and the accompanying form of proxy to the purchaser or the transferee or to the bank, licensed securities dealer or other agent through whom the sale or the transfer was effected for onward transmission to the purchaser or the transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



WAI YUEN TONG MEDICINE HOLDINGS LIMITED (位元堂藥業控股有限公司*)

(Incorporated in Bermuda with limited liability)
(Stock Code: 897)

PROPOSALS FOR GRANT OF NEW ISSUE MANDATE AND NEW REPURCHASE MANDATE, RE-ELECTION OF DIRECTORS, REFRESHMENT OF SCHEME MANDATE LIMIT AND NOTICE OF ANNUAL GENERAL MEETING

A notice convening the AGM of the Company to be held at Garden Rooms A & B, 2/F., Hotel Nikko Hongkong, 72 Mody Road, Tsimshatsui, Kowloon, Hong Kong on Wednesday, 18 August 2010 at 10:45 a.m. is set out on pages 17 to 21 of this circular.

Whether or not you intend to attend and vote in person at the AGM, you are requested to complete the enclosed form of proxy in accordance with the instructions printed thereon and return it to the Company's branch share registrar and transfer office in Hong Kong, Tricor Secretaries Limited at 26/F., Tesbury Centre, 28 Queen's Road East, Wanchai, Hong Kong as soon as practicable but in any event not later than 48 hours before the time appointed for the holding of the AGM or any adjournment thereof (as the case may be). Completion and return of the form of proxy will not preclude you from subsequently attending and voting in person at the AGM or any adjournment thereof (as the case may be) should you so wish and in such event, the instrument appointing a proxy shall be deemed to be revoked.

* For identification purpose only

CONTENTS

	Page
Definitions	1
Letter from the Board	
Introduction	5
Grant of the New Issue Mandate and the New Repurchase Mandate	6
Re-election of the Directors	7
Refreshment of the Scheme Mandate Limit	7
Responsibility Statement	9
AGM	9
Recommendation	10
Appendix I — Explanatory Statement on the New Repurchase Mandate	11
Appendix II — Details of Retiring Directors Proposed for Re-election	14
Notice of the ACM	17

DEFINITIONS

In this circular, unless the context otherwise specifics, the following expressions have the following meanings:

"AGM"

the annual general meeting of the Company to be held at Garden Rooms A & B, 2/F., Hotel Nikko Hongkong, 72 Mody Road, Tsimshatsui, Kowloon, Hong Kong, on Wednesday, 18 August 2010 at 10:45 a.m. or at any adjournment thereof (as the case may be)

"Announcement"

the announcement of the Company dated 12 April 2010 in respect of the Placing

"associate"

has the same meaning ascribed thereto under the Listing Rules

"Board"

the board of Directors

"Bye-laws"

the bye-laws of the Company

"Code"

the Hong Kong Code on Takeovers and Mergers

"Company"

Wai Yuen Tong Medicine Holdings Limited (位元堂藥業控股有限公司*), an exempted company incorporated in Bermuda with limited liability and the shares of which are listed on the

main board of the Stock Exchange

"connected person(s)"

has the same meaning ascribed thereto under the Listing Rules

"Directors"

the director(s) of the Company

"Eligible Participants"

- (i) (a) any director or proposed director (whether executive or non-executive, including any independent non-executive director), employee or proposed employee (whether full time or part time) of, or
 - (b) any individual for the time being seconded to work for,

any member of the Group or any substantial shareholder or any company controlled by a substantial shareholder; or

(ii) any holder of any securities issued by any member of the Group or any substantial shareholder or any company controlled by a substantial shareholder; or

^{*} For identification purpose only

DEFINITIONS

- (iii) (a) any business or joint venture partner, contractor, agent or representative of,
 - (b) any person or entity that provides research, development or other technological support or any advisory, consultancy, professional or other services to,
 - (c) any supplier, producer or licensor of goods or services to,
 - (d) any customer, licensee (including any sub-licensee) or distributor of goods or services of, or
 - (e) any landlord or tenant (including any sub-tenant) of,

any member of the Group or any substantial shareholder or any company controlled by a substantial shareholder;

and, for the purposes of the Share Option Scheme, shall include any company controlled by one or more persons belonging to any of the above classes of participants

the Company and its subsidiaries

Hong Kong dollar(s), the lawful currency of Hong Kong

the Hong Kong Special Administrative Region of the PRC

13 July 2010, being the latest practicable date prior to the printing of this circular for the purpose of ascertaining certain information for inclusion in this circular

LeRoi Holdings Limited, a company incorporated in the Cayman Islands with limited liability and the shares of which are listed on the main board of the Stock Exchange

the Rules Governing the Listing of Securities on the Stock Exchange

"Group"

"HK\$"

"Hong Kong"

"Latest Practicable Date"

"LeRoi"

"Listing Rules"

DEFINITIONS

"New Issue Mandate"

a general and unconditional mandate proposed to be granted to the Directors at the AGM to allot, issue and deal with additional Shares and other securities up to a maximum of 20% of the aggregate nominal amount of the share capital of the Company in issue as at the date of passing of the relevant resolution granting the New Issue Mandate

"New Repurchase Mandate"

a general and unconditional mandate proposed to be granted to the Directors to exercise the powers of the Company to repurchase Shares on the Stock Exchange during the prescribed period up to a maximum of 10% of the aggregate nominal amount of the share capital of the Company in issue as at the date of passing the relevant resolution granting the New Repurchase Mandate

"Partial Share Exchange Offer"

the voluntary conditional partial share exchange offer being made by Kingston Securities Limited on behalf of Gain Better Investments Limited, a wholly-owned subsidiary of the Company, to acquire 1,463,835,000 shares in LeRoi from the independent LeRoi shareholders on the basis of five (5) new Shares for every two (2) shares in LeRoi

"Placing"

placing of 1,200,000,000 new Shares at a price of HK\$0.053 per Share under the general mandate granted to the Directors at the special general meeting held on 2 February 2010, details of which are set out in the Announcement

"PRC"

The People's Republic of China and for the purpose of this circular shall exclude Hong Kong, the Macau Special Administrative Region of the People's Republic of China and Taiwan

"Scheme Mandate Limit"

the maximum number of the Shares (being up to 10% of the Shares in issue as at the date of the relevant general meeting) which may be issued upon exercise of all Share Options to be granted under the Share Option Scheme as at the date of adoption of the Share Option Scheme or as refreshed from time to time

"Scheme Period"

the period commencing on the date on which the Share Option Scheme was adopted by the Shareholders and expiring at the close of business on the day immediately preceding the tenth anniversary thereof

"SFO"

the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)

"Shareholder(s)"

the holder(s) of the Share(s)

DEFINITIONS			
"Share Option(s)"	the option(s) to subscribe for Shares granted under the Share Option Scheme		
"Share Option Scheme"	the share option scheme adopted by the Shareholders at the special general meeting of the Company held on 18 September 2003		
"Share(s)"	the ordinary share(s) with a nominal value of HK\$0.01 each in the share capital of the Company		
"Stock Exchange"	The Stock Exchange of Hong Kong Limited		
"substantial shareholder(s)"	has the same meaning ascribed thereto under the Listing Rules		
"Wang On Group"	Wang On Group Limited (宏安集團有限公司)*, a major shareholder of the Company and the shares of which are listed on the main board of the Stock Exchange, and its subsidiaries		
"%"	per cent.		

^{*} For identification purpose only



WAI YUEN TONG MEDICINE HOLDINGS LIMITED (位元堂藥業控股有限公司*)

(Incorporated in Bermuda with limited liability)

(Stock Code: 897)

Executive Directors:

Mr. Tang Ching Ho (Chairman)
Mr. Chan Chun Hong, Thomas
(Managing Director)
Ms. Tang Mui Fun

Independent non-executive Directors:

Mr. Leung Wai Ho Mr. Yuen Chi Choi Mr. Siu Man Ho, Simon Mr. Cho Wing Mou Registered office: Clarendon House 2 Church Street Hamilton HM 11 Bermuda

Head office and
principal place of business:
5/F., Wai Yuen Tong Medicine Building
9 Wang Kwong Road
Kowloon Bay
Kowloon
Hong Kong

16 July 2010

To the Shareholders and, for information only, the holders of the Share Options

Dear Sir or Madam,

PROPOSALS FOR GRANT OF NEW ISSUE MANDATE AND NEW REPURCHASE MANDATE, RE-ELECTION OF DIRECTORS, REFRESHMENT OF SCHEME MANDATE LIMIT AND NOTICE OF ANNUAL GENERAL MEETING

INTRODUCTION

The purpose of this circular is to provide you with information and to seek your approval to the proposed (i) grant of the New Issue Mandate and the New Repurchase Mandate; (ii) the extension of the New Issue Mandate by the addition of the number of Shares repurchased pursuant to the New Repurchase Mandate; (iii) re-election of the retiring Directors; and (iv) refreshment of Scheme Mandate Limit. A notice of the AGM containing the resolutions to be proposed at the AGM is set out on pages 17 to 21 of this circular.

^{*} For identification purpose only

GRANT OF THE NEW ISSUE MANDATE AND THE NEW REPURCHASE MANDATE

At the Company's last annual general meeting held on 26 August 2009, the Directors were granted a general mandate to allot, issue and deal with Shares with an aggregate value of not exceeding 20% of the aggregate nominal amount of the issued share capital of the Company as at 26 August 2009 (equivalent to the aggregate nominal amount of HK\$4,824,703.37 divided into 482,470,337 Shares with a nominal value of HK\$0.01 each) (the "2009 General Mandate") and a general mandate to repurchase Shares up to a maximum 10% of the aggregate nominal amount of the issued share capital of the Company as at 26 August 2009 (equivalent to the aggregate nominal amount of HK\$2,412,351.68 dividend into 241,235,168 Shares with a nominal value of HK\$0.01 each) (the "2009 Repurchase Mandate").

Although the 2009 General Mandate and the 2009 Repurchase Mandate had not been utilised, the total number of the issued share capital of the Company had been substantially increased to 6,071,939,188 Shares immediately following the issue and allotment of 3,659,587,500 Shares pursuant to completion of the Partial Share Exchange Offer. At the special general meeting of the Company held on 2 February 2010, ordinary resolutions were passed by the independent Shareholders and the Shareholders respectively to refresh (i) the 2009 General Mandate and extension thereof to the Directors to allot, issue and deal with 1,214,387,837 Shares, representing 20% of the issued share capital of the Company as at 2 February 2010 (the "Refreshed 2009 General Mandate"); and (ii) the 2009 Repurchase Mandate to the Directors to repurchase the Shares up to 607,193,918 Shares, representing 10% of the issued share capital of the Company as at 2 February 2010 (the "Refreshed 2009 Repurchase Mandate").

On 12 April 2010, the Company entered into an agreement with a placing agent in respect of the Placing, completion of which took place on 22 April 2010, as detailed in the Company's announcements dated 12 April 2010 and 22 April 2010. Aggregate net proceeds of approximately HK\$61.5 million were raised for the repayment of interest-bearing debts, expansion of the Group's Chinese and Western health food and pharmaceutical business (including, if and when attractive opportunities arise, the acquisition of appropriate retail premises for use by the Group's retail network) and general working capital. As such, the Refreshed 2009 General Mandate was almost utilised. The Refreshed 2009 Repurchase Mandate had not been utilsed and will expire at the conclusion of the AGM.

To facilitate future allotment and issue of Shares by the Directors on behalf of the Company, the Directors will seek the approval of the Shareholders for the grant of:

- (a) the New Issue Mandate;
- (b) the New Repurchase Mandate; and
- (c) if the New Repurchase Mandate is granted, a general mandate to add the aggregate number of Shares repurchased by the Company under the New Repurchase Mandate to the New Issue Mandate, subject to a maximum of 10% of the issued share capital of the Company as at the date of passing of the relevant resolution.

The Directors have no immediate plans to allot and issue any new Shares under the New Issue Mandate and such Shares which may fall to be issued upon the exercise of the outstanding Share Options granted.

An explanatory statement in respect of the New Repurchase Mandate required under the Listing Rules is set out in Appendix I to this circular.

RE-ELECTION OF THE DIRECTORS

In accordance with Bye-law 87 of the Bye-laws, Ms. Tang Mui Fun, Mr. Leung Wai Ho and Mr. Siu Man Ho, Simon will retire as Directors by rotation at the AGM and, being eligible, offer themselves for re-election.

Details of Ms. Tang Mui Fun, Mr. Leung Wai Ho and Mr. Siu Man Ho, Simon required to be disclosed pursuant to the Listing Rules are set out in Appendix II to this circular.

Biographical details of each of Ms. Tang Mui Fun, Mr. Leung Wai Ho and Mr. Siu Man Ho, Simon required to be disclosed by the Listing Rules are set out in the Appendix II to this circular. If a valid notice from a Shareholder to propose a person to stand for election as a Director at the AGM is received in accordance with the Bye-laws after the printing of this circular, the Company will issue a supplementary circular to inform Shareholders of the details of such additional candidate(s) proposed.

REFRESHMENT OF THE SCHEME MANDATE LIMIT

The Company adopted the Share Option Scheme pursuant to a resolution passed by the Shareholders at the special general meeting held on 18 September 2003 in accordance with the requirements set out in Chapter 17 of the Listing Rules. The purpose of the Share Option Scheme is to provide incentives and rewards to Eligible Participants who contribute to the success of the operations of the Group. As at the Latest Practicable Date, apart from the Share Option Scheme, the Company did not have any other share option schemes.

Under the rules of the Share Option Scheme:

(1) Subject to sub-paragraphs (2) and (3) below, the maximum number of Shares issuable upon exercise of all options to be granted under the Share Option Scheme and any other share option schemes of the Company as from the commencement of the Scheme Period (excluding, for this purpose, Share Options which have lapsed in accordance with the terms of the Shares Option Scheme or any other share option schemes of the Company) must not in aggregate exceed the Scheme Mandate Limit. The Shares underlying any Share Options granted under the Share Options Scheme or any other share option schemes of the Company which have been cancelled (but not Share Options which have lapsed) are counted for the purpose of calculating the Scheme Mandate Limit.

- (2) The Scheme Mandate Limit may be refreshed at any time by obtaining approval of the Shareholders in general meeting provided that the new limit under the refreshed Scheme Mandate Limit must not exceed 10% of the Shares in issue at the date of the Shareholder's approval of such refreshed Scheme Mandate Limit. Share Options previously granted under the Share Option Scheme or any other share option schemes of the Company (including those exercised, outstanding, cancelled or lapsed in accordance with the terms of the Share Option Scheme or any other share option schemes of the Company) will not be counted for the purpose of calculating the total number of Shares subject to the refreshed Scheme Mandate Limit.
- (3) The aggregate number of Shares which may be issued upon exercise of all outstanding Share Options granted and yet to be exercised under the Share Option Scheme and any other share option schemes of the Company must not exceed 30% of the Shares in issue from time to time.

At annual general meeting held on 17 August 2006, the Scheme Mandate Limit was refreshed to allow the Company to grant Share Options entitling holders to subscribe for Shares not exceeding 10% of the issued share capital of the Company as at the date of approving the refreshment, which amounted to 139,634,768 Shares (the "2006 Refreshed Scheme Mandate Limit").

The Company granted an aggregate of 27,830,000 Share Options during period from January 2007 to May 2010 to allow the Eligible Participants to subscribe for an aggregate of 27,830,000 Shares represented approximately 19.9% of the 2006 Refreshed Scheme Mandate Limit, of which no Share Option was exercised, 5,460,000 Share Options were lapsed/cancelled and 22,370,000 remained outstanding entitling the holders of the Share Options to subscribe for an aggregate of 22,370,000 new Shares, representing approximately 0.31% of the total issued share capital of the Company as at the Latest Practicable Date.

Following the Share Options granted in May 2010, the outstanding 2006 Refreshed Scheme Mandate Limit entitling the Company to issue Share Options to Eligible Participants under the Share Option Scheme has been reduced to 111,804,768 Share Options, representing 1.54% of the total issued share capital of the Company as at the Latest Practicable Date.

The issued share capital of the Company has been enlarged substantially since 17 August 2006 as a result of the issue of the new Shares pursuant to, inter alia, the Partial Share Exchange Offer completed in November 2009 and the various placing activities in 2008 and 2009, the Directors are of the view that the refreshment of the Scheme Mandate Limit will enable the Company to grant further Share Options to Eligible Participants who, at the sole discretion of the Board, will contribute or has contributed to the Group as incentives or rewards. As at the Latest Practicable Date, there were 7,271,939,188 Shares in issue. Assuming no further Shares are/will be issued and allotted prior to the date of the AGM, the maximum number of Share Options that can be granted by the Company under the refreshed Scheme Mandate Limit would be 727,193,918. According to the rules and requirements of the Share Option Scheme and the Listing Rules, an ordinary resolution will be proposed at the AGM to approve the proposed "refreshed" Scheme Mandate Limit.

As at the Latest Practicable Date, there were 22,370,000 Share Options outstanding under the Share Option Scheme, representing 0.31% of the issued share capital of the Company. The aggregate

maximum number of the Shares that can be issued pursuant to the Share Options to be granted under the refreshed Scheme Mandate Limit and the existing number of Shares to be issued upon the exercise of the outstanding Share Options granted under the Share Option Scheme and any other share option schemes adopted by the Company were 749,563,918 Shares, representing 10.31% of the total issued share capital of the Company and did not exceed 30% of the Shares in issue as at the Latest Practicable Date.

The refreshment of the Scheme Mandate Limit is conditional upon:

- (a) the passing of an ordinary resolution by the Shareholder at the AGM to approve, among other things, the refreshment of the Scheme Mandate Limit; and
- (b) the Listing Committee of the Stock Exchange granting the approval of the listing of, and permission to deal in, 10% of the Shares in issue at the date of approval of the refreshment of the Scheme Mandate Limit which may be issued upon exercise of any Share Option granted under the refreshed Scheme Mandate Limit.

Application will be made to the Listing Committee of the Stock Exchange for the listing of, and permission to deal in, the Shares which may fall to be issued upon the exercise of any share options that may be granted under the refreshed Scheme Mandate Limit.

RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Group. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

AGM

A notice of the AGM, which is convened for the purpose of considering and, if thought fit, approving, among other things, the grant of the New Issue Mandate and the New Repurchase Mandate, the re-election of the retiring Directors and the refreshment of the Scheme Mandate Limit, is set out on pages 17 to 21 of this circular.

Pursuant to Rules 13.39(4) and 13.39(5) of the Listing Rules and the Bye-laws, the voting on all proposed resolutions will be taken by way of a poll and an announcement on the poll results will be made by the Company after the AGM.

A form of proxy for use at the AGM is enclosed with this circular. Whether or not you intend to attend and vote in person at the AGM, you are requested to complete the enclosed form of proxy in accordance with the instructions printed thereon and return it to the Company's branch share registrar and transfer office in Hong Kong, Tricor Secretaries Limited at 26/F., Tesbury Centre, 28

Queen's Road East, Wanchai, Hong Kong as soon as practicable but in any event not later than 48 hours before the time appointed for the holding of the AGM or any adjournment thereof (as the case may be). Completion and return of the form of proxy will not preclude you from subsequently attending and voting in person at the AGM or any adjournment thereof (as the case may be) should you so wish and in such event, the instrument appointing a proxy shall be deemed to be revoked.

RECOMMENDATION

The Board considers that the proposals for (i) the grant of the New Issue Mandate and the New Repurchase Mandate; (ii) the extension of the New Issue Mandate by the addition of the number of Shares repurchased pursuant to the New Repurchase Mandate; (iii) the re-election of the retiring Directors; and (iv) the refreshment of the Scheme Mandate Limit, are in the best interests of the Company and the Shareholders as a whole and, accordingly, the Board recommends all Shareholders to vote in favour of the relevant resolutions to be proposed at the AGM in respect thereof.

Yours faithfully,
For and on behalf of the Board

Wai Yuen Tong Medicine Holdings Limited
(位元堂藥業控股有限公司*)

Tang Ching Ho

Chairman

^{*} For identification purpose only

This appendix serves as an explanatory statement, as required by the Listing Rules, to provide the requisite information to you for your consideration in respect of the New Repurchase Mandate. For the purpose of this appendix, the term "Shares" (unless otherwise stated) shall be as defined in the Code on the Share Repurchases which means shares of all classes and securities which carry a right to subscribe for or purchase shares.

1. SHARE CAPITAL

As at the Latest Practicable Date, the issued share capital of the Company was HK\$72,719,391.88, comprising 7,271,939,188 Shares, and the outstanding Share Options was 22,370,000 Shares. If such outstanding Share Options are exercised in full on or prior to the date of passing of the resolution in respect of the New Repurchase Mandate, a further 22,370,000 Shares will be in issue.

Subject to the passing of the relevant resolution(s) as set out in the notice of the AGM and assuming that no further Shares were/will issued and/or repurchased by the Company between the Latest Practicable Date and the date of AGM, the Directors will be authorised to purchase up to 727,193,918 Shares pursuant to the New Repurchase Mandate. Assuming that rights attached to all outstanding Share Options is exercised in full on or before the date of passing of the resolution in respect of the New Repurchase Mandate and assuming no further Shares were/will be issued and/or repurchased by the Company, the total number of Shares in issue will be 7,294,309,188 and the Directors will be authorised to repurchase with an aggregate nominal amount up to HK\$7,294,309.18 (representing 729,430,918 Shares with a nominal value of HK\$0.01 each).

2. REASONS FOR REPURCHASES

The Directors believe that it is in the best interests of the Company and its Shareholders to have a general authority from the Shareholders to enable the Directors to repurchase Shares in the market.

Such repurchases may, depending on market conditions and funding arrangements at the time, lead to an enhancement of the net value of the Company and/or its assets and/or its earnings per Share and will only be made when the Directors believe that such repurchases will benefit the Company and its Shareholders as a whole.

3. FUNDING OF REPURCHASES

In repurchasing Shares, the Company may only apply funds legally for such purpose in accordance with its memorandum of association and the Bye-laws, the laws of Bermuda and other applicable laws.

There might be an adverse impact on the working capital or gearing position of the Company as compared with the positions disclosed in the audited consolidated financial statements contained in the annual report for the year ended 31 March 2010 in the event that the New Repurchase Mandate was to be carried out in full at any time during the proposed repurchase period.

However, the Directors do not propose to exercise of the New Repurchase Mandate to such extent as would, in the circumstances, have a material adverse effect on the working capital or the gearing level of the Company which in the opinion of the Directors is from time to time appropriate for the Company.

4. DIRECTORS, THEIR ASSOCIATES AND CONNECTED PERSONS

None of the Directors nor, to the best of their knowledge having made all reasonable enquiries, any of their associates, have any present intention to sell any Shares to the Company under the New Repurchase Mandate if such is approved by the Shareholders.

No connected persons have notified the Company that he has a present intention to sell Shares to the Company, or that he has undertaken not to do so, in the event that the New Repurchase Mandate is approved by the Shareholders at the AGM.

5. DIRECTORS' UNDERTAKING

The Directors have undertaken to the Stock Exchange that, so far as the same may be applicable, they will exercise the power of the Company to make repurchases pursuant to the New Repurchase Mandate in accordance with the Listing Rules, the memorandum of association of the Company, the Bye-laws and the applicable laws of Bermuda so far as the same may be applicable.

6. EFFECT OF THE CODE

If, on the exercise of the power to repurchase Shares pursuant to the New Repurchase Mandate, a Shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition for the purpose of Rule 32 of the Code. As a result, a Shareholder or a group of Shareholders acting in concert (as defined in the Code), depending on the level of such increase, could obtain or consolidate control of the Company and may become obliged to make a mandatory offer in accordance with Rules 26 and 32 of the Code.

As at the Latest Practicable Date and to the best knowledge and belief of the Directors, Wang On Group, and parties acting in concert with it, were deemed to be interested in approximately 7.25% of the issued share capital of the Company. In the event that the Directors should exercise in full the power to repurchase Shares under the New Repurchase Mandate and if there is no other change in the issued share capital of the Company, the shareholding of Wang On Group in the Company will be increased to approximately 8.05% of the issued share capital of the Company. The Directors are not aware of any consequence which may arise under the Code as a result of any repurchases made under the New Repurchase Mandate.

The Directors have no present intention to exercise the power to repurchase the Shares to the extent that the aggregate amount of the share capital of the Company in public hands would be reduced to less than 25%.

7. SHARE PURCHASE MADE BY THE COMPANY

The Company had not purchased any of its Shares (whether on the Stock Exchange or otherwise) in the six months preceding the date of the Latest Practicable Date.

8. SHARE PRICES

The highest and lowest prices at which the Shares have traded on the Stock Exchange during each of the previous twelve months up to the Latest Practicable Date were as follows:

	Price per Share	
	Highest	Lowest
Month	HK\$	HK\$
2009		
July	0.112	0.101
August	0.118	0.096
September	0.114	0.097
October	0.107	0.099
November	0.126	0.099
December	0.105	0.085
2010		
January	0.092	0.066
February	0.075	0.063
March	0.068	0.046
April	0.075	0.053
May	0.057	0.043
June	0.051	0.044
July (up to and including the Latest Practicable Date)	0.048	0.045

The biographical details of Ms. Tang Mui Fun, Mr. Leung Wai Ho and Mr. Siu Man Ho, Simon, who are proposed to be re-elected at the AGM, are as follows:

1. **Ms. Tang Mui Fun**, aged 39, joined the Group in 2000 and was appointed as the Executive Director in September 2007. She is responsible for the overall strategic planning and development and policy making for the core business of the Group. She graduated from the University of Hull (England) with a bachelor degree in accountancy. Prior to joining the Group, she had four years of experience in the accounting and auditing fields and five years of experience in general management. She is a sister of Mr. Tang Ching Ho, the Chairman of the Company. Save as disclosed above, as at the Latest Practicable Date, Ms. Tang did not hold any other directorship in listed public companies during the past three years.

Pursuant to the service contract entered into between the Company and Ms. Tang, Ms. Tang is entitled to a director's fee of approximately HK\$1.6 million per annum. She is also entitled to bonus and other benefits at the discretion of the Board by reference to the Company's performance and the prevailing practice in the industry. The terms of Ms. Tang's appointment is subject to the retirement by rotation and re-election at any subsequent annual general meeting of the Company in accordance with the provisions of the Bye-laws.

Save as disclosed above, as at the Latest Practicable Date, Ms. Tang did not have any relationship with any other Directors, senior management, substantial or controlling Shareholders (as defined in the Listing Rules), nor have any interest in Shares within the meaning of Part XV of the SFO.

There is no information which is discloseable nor is/was Ms. Tang involved in any of the matters required to be disclosed pursuant to any of the requirements of the provisions under paragraphs 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, and the Directors are not aware of any other matters regarding the re-election of Ms. Tang that needs to be bought to the attention of the Shareholders.

2. Mr. Leung Wai Ho, aged 60, was re-designated as an Independent Non-executive Director in April 2006 from non-executive Director and has joined the Group since 1994. Mr. Leung is a member of audit committee, remuneration committee and nomination committee of the Company. He has more than 45 years' and 16 years' of experiences in watch industry and financial industry respectively. He is a National Committee Member of the Chinese People's Political Consultative Conference, a Standing Committee Member of Hebei Province of the Chinese People's Political Consultative Conference, a Standing Committee Member of The Chinese General Chamber of Commerce, a Committee Member of The Chinese Manufacturers' Association of Hong Kong, a Honorary President of Hong Kong Chamber of Commerce in China — Guangdong. Mr. Leung was re-designated to the Chartered President of Dongguan City Association of Enterprises with Foreign Investment. Save as disclosed above, as at the Latest Practicable Date, Mr. Leung did not hold any other directorship in listed public companies during the past three years.

Mr. Leung has entered into a service contract with the Company for not more than three years. In accordance with the terms of the service contract, Mr. Leung is entitled to a director's fee of HK\$120,000 per annum and will also be entitled to a fee in the amount of HK\$20,000 per annum determined with reference to his duties as a member of the audit committee of the Company. The terms of Mr. Leung's appointment is subject to the retirement by rotation and re-election at any subsequent annual general meeting of the Company in accordance with the Bye-laws.

As at the Latest Practicable Date, Mr. Leung did not have any relationship with any other Directors, senior management, substantial or controlling Shareholders (as defined in the Listing Rules) nor have any interest in the Shares within the meaning of Part XV of the SFO. Also, as at the Latest Practicable Date, he did not hold any other positions with the Company or any member of the Group.

There is no information which is discloseable nor is/was Mr. Leung involved in any of the matters required to be disclosed pursuant to any of the requirements of the provisions under paragraphs 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, and the Directors are not aware of any other matters regarding the re-election of Mr. Leung that needs to be bought to the attention of the Shareholders.

3. **Mr. Siu Man Ho, Simon**, aged 36, joined the Company as an Independent Non-executive Director in August 2001. He is a member of audit committee and nomination committee of the Company and the chairman of remuneration committee of the Company. Mr. Siu is a practising solicitor of the High Court of Hong Kong. He obtained a bachelor of Laws degree from the University of Hong Kong in 1996 and is a partner of the law firm, namely Sit, Fung, Kwong & Shum. His areas of practice include corporate finance, capital markets, securities, mergers and acquisitions, joint ventures and general commercial matters. Save as disclosed above, as at the Latest Practicable Date, Mr. Siu did not hold any other directorship in listed public companies during the past three years.

Mr. Siu has entered into a service contract with the Company for not more than three years. In accordance with the terms of the service contract, Mr. Siu is entitled to a director's fee of HK\$120,000 per annum and will also be entitled to a fee in the amount of HK\$20,000 per annum determined with reference to his duties as a member of the audit committee of the Company. The terms of Mr. Siu's appointment is subject to the retirement by rotation and re-election at any subsequent annual general meeting of the Company in accordance with the Bye-laws.

As at the Latest Practicable Date, Mr. Siu did not have any relationship with any other Directors, senior management, substantial or controlling Shareholders (as defined in the Listing Rules) nor have any interest in the Shares within the meaning of Part XV of the SFO. Also, as at the Latest Practicable Date, he did not hold any other positions with the Company or any member of the Group.

APPENDIX II DETAILS OF RETIRING DIRECTORS PROPOSED FOR RE-ELECTION

There is no information which is discloseable nor is/was Mr. Siu involved in any of the matters required to be disclosed pursuant to any of the requirements of the provisions under paragraphs 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, and the Directors are not aware of any other matters regarding the re-election of Mr. Siu that needs to be bought to the attention of the Shareholders.



WAI YUEN TONG MEDICINE HOLDINGS LIMITED (位元堂藥業控股有限公司*)

(Incorporated in Bermuda with limited liability)
(Stock Code: 897)

NOTICE OF ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that the annual general meeting of Wai Yuen Tong Medicine Holdings Limited (位元堂藥業控股有限公司*)(the "Company") will be held at Garden Rooms A & B, 2/F., Hotel Nikko Hongkong, 72 Mody Road, Tsimshatsui, Kowloon, Hong Kong, on Wednesday, 18 August 2010 at 10:45 a.m. for the following purposes:

AS ORDINARY BUSINESS

- 1. To receive, consider and adopt the audited consolidated financial statements and the reports of the directors and auditors for the year ended 31 March 2010.
- 2. To re-elect the following directors and to authorise the board of directors (the "Board" or the "Director") to fix the remuneration of the Directors:
 - (i) Ms. Tang Mui Fun as an executive Director;
 - (ii) Mr. Leung Wai Ho as an independent non-executive Director; and
 - (iii) Mr. Siu Man Ho, Simon as an independent non-executive Director.
- 3. To re-appoint Deloitte Touche Tohmatsu as auditors of the Company and to authorise the Board to fix their remuneration.

AS SPECIAL BUSINESS, to consider and, if thought fit, pass with or without amendments the following resolutions as ordinary resolutions of the Company:

4. (A) "**THAT**:

(a) subject to paragraph (b) below, the exercise by the Directors during the Relevant Period (as hereafter defined) of all the powers of the Company to repurchase shares in the capital of the Company (the "Shares") be and is hereby general and unconditionally approved;

^{*} For identification purpose only

- (b) the aggregate nominal amount of Share which may be repurchased or agreed to repurchased by the Company pursuant to the approval in paragraph (a) above shall not exceed 10% of the aggregate nominal amount of the share capital of the Company in issue at the date of the passing of this resolution and the said approval shall be limited accordingly; and
- (c) for the purpose of this resolution:

"Relevant Period" means the period from the passing of this resolution until whichever is the earliest of:

- (i) the conclusion of the next annual general meeting of the Company;
- (ii) the expiration of the period within which the next annual general meeting of the Company is required by laws of Bermuda or the Company's bye-laws to be held;or
- (iii) the revocation or variation of the authority given under this resolution by an ordinary resolution of the shareholders of the Company in general meeting."

(B) "THAT:

- (a) subject to paragraph (c) below, the exercise by the Directors during the Relevant Period (as hereinafter defined) of all the powers of the Company to allot, issue and deal with additional Shares, and to make or grant offers, agreements and options which would or might require the exercise of such powers, subject to and in accordance with all applicable laws, be and is hereby generally and unconditionally approved;
- (b) the approval in paragraph (a) above shall be in addition to any other authorisations given to the Directors and shall authorise the Directors during the Relevant Period to make or grant offers, agreements and options which might require the exercise of such powers after the end of the Relevant Period;
- (c) the aggregate nominal amount of the share capital allotted or agreed conditionally or unconditionally to be allotted (whether pursuant to an option or otherwise) by the Directors pursuant to the approval in paragraph (a) above, otherwise than pursuant to:
 - (i) a Right Issue (as hereinafter defined);
 - (ii) the exercise of rights subscription or conversion under terms of any warrants issued by the Company or any securities which are convertible into Shares;

- (iii) the exercise of any option under the share option scheme or similar arrangement for the time being adopted for the grant or issue to officers and/or employees of the Company and/or any of its subsidiaries of Shares or rights to acquire Shares; and
- (iv) any scrip dividend or similar arrangement providing for the allotment of Shares in lieu of the whole or part of a dividend on the Shares in accordance with the bye-laws of the Company in force from time to time,

shall not exceed the aggregate of (aa) 20% of the aggregate nominal amount of the share capital of the Company in issue at the date of the passing of this resolution; and (bb) (if the Directors are so authorised by a separate ordinary resolution of the shareholders of the Company) the aggregate nominal amount of any shares capital of the Company repurchased by the Company subsequent to the passing of this resolution (up to a maximum equivalent to 10% of the aggregate nominal amount of the share capital of the Company in issue at the date of the passing of this resolution), the said approval shall be limited accordingly; and

(d) for the purpose of this resolution:

"Relevant Period" means the period from the passing of this resolution until whichever is the earliest of:

- (i) the conclusion of the next annual general meeting of the Company;
- (ii) the expiration of the period within which the next annual general meeting of the Company is required by Bermuda law or the Company's bye-laws to be held; or
- (iii) the revocation or variation of the authority given under this resolution by an ordinary resolution of the shareholders of the Company in general meeting; and

"Rights Issue" means the allotment, issue or grant of Shares pursuant to an offer of Shares open for a period fixed by the Directors to holders of Shares or any class thereof on the register of members on a fixed record date in proportion to their then holdings of such Shares or class thereof (subject to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements or having regard to any restrictions or obligations under the laws of, or the requirements of, any recognised regulatory body or stock exchange in any territory outside Hong Kong)."

- (C) "THAT, conditional upon the passing of resolutions numbered 4(A) and 4(B) above, the general mandate granted to the Directors to exercise the powers of the Company to allot, issue and otherwise deal with additional Shares of the Company pursuant to the resolution numbered 4(B) above be and is hereby extended by the addition to the aggregate nominal amount of the share capital of the Company which may be allotted and issued or agreed conditionally or unconditionally to be allotted and issued by the Directors pursuant to such general mandate an amount representing the aggregate nominal amount of the share capital of the Company repurchased or agreed to be repurchased by the Company since the granting of the general mandate pursuant to resolution numbered 4(A) above, provided that such amount shall not exceed 10% of the aggregate nominal amount of the share capital of the Company in issue at the date of the passing of this resolution."
- 5. "THAT conditional upon the Listing Committee of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") granting the listing of, and permission to deal in, Shares to be issued pursuant to the exercise of options which may be granted under the New Scheme Limit (as defined below), the refreshment of the scheme mandate limit of the Company's share option scheme adopted on 18 September 2003 and all other share option scheme(s) of the Company, up to 10% of the number of shares in issue as at the date of passing this resolution (the "New Scheme Limit") be and is hereby approved and any director of the Company be and is hereby authorised to do such act and execute such documents to effect the New Scheme Limit and to exercise all powers of the Company to allot, issue and deal with the Shares to be issued pursuant to the exercise of such options."

By Order of the Board
Wai Yuen Tong Medicine Holdings Limited
(位元堂藥業控股有限公司*)
Mak Yuen Ming, Anita
Company Secretary

Hong Kong, 16 July 2010

* For identification purpose only

Notes:

- (1) A member entitled to attend and vote at the annual general meeting convened by the above notice, is entitled to appoint one or if such member is a holder of more than one share, more than one proxy to attend and to vote in his stead. A proxy need not be a member of the Company.
- (2) In order to be valid, the form of proxy, together with any power of attorney or other authority, if any, under which it is signed, or a certified copy of such power or authority, must be deposited at the Company's branch share registrar and transfer office in Hong Kong, Tricor Secretaries Limited at 26/F., Tesbury Centre, 28 Queen's Road East, Wanchai, Hong Kong as soon as practicable and in any event not later than 48 hours before the time appointed for the holding of the annual general meeting or any adjournment thereof (as the case may be). Completion and return of the form of proxy will not preclude members from attending and voting at the annual general meeting or any adjournment thereof (as the case may be), if they so wish and in such event, the instrument appointing a proxy shall be deemed to be revoked.
- (3) Where there are joint holders of any shares, any one of such joint holders may vote at the annual general meeting either personally or by proxy in respect of such shares as if he was solely entitled thereto provided that if more than one of such joint holders be present at the annual general meeting whether personally or by proxy, the person whose name stands first on the register of members of the Company in respect of such shares shall be accepted to the exclusion of the votes of the other joint holders.
- (4) All of the above resolutions numbered (1) to (5) will be voted by way of a poll at the annual general meeting.